S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
Log in

NYSE:NVRO - Nevro Stock Price, Forecast & News

$144.31
+1.72 (+1.21 %)
(As of 02/19/2020 04:00 PM ET)
Today's Range
$142.30
Now: $144.31
$145.56
50-Day Range
$114.31
MA: $128.05
$142.59
52-Week Range
$41.25
Now: $144.31
$145.56
Volume337,900 shs
Average Volume397,833 shs
Market Capitalization$4.47 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.46
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone650-251-0005

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$387.29 million
Book Value$8.14 per share

Profitability

Net Income$-49,210,000.00

Miscellaneous

Employees804
Market Cap$4.47 billion
Next Earnings Date2/25/2020 (Confirmed)
OptionableOptionable

Receive NVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter.


Nevro (NYSE:NVRO) Frequently Asked Questions

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

How were Nevro's earnings last quarter?

Nevro Corp (NYSE:NVRO) released its quarterly earnings data on Wednesday, November, 6th. The medical equipment provider reported ($0.58) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.85) by $0.27. The medical equipment provider had revenue of $100.16 million for the quarter, compared to analysts' expectations of $92.27 million. Nevro had a negative return on equity of 46.35% and a negative net margin of 25.94%. Nevro's quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.37) earnings per share. View Nevro's Earnings History.

When is Nevro's next earnings date?

Nevro is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Nevro.

How can I listen to Nevro's earnings call?

Nevro will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Nevro issued on next quarter's earnings?

Nevro updated its fourth quarter 2019 Pre-Market earnings guidance on Tuesday, January, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $114.4-114.4 million, compared to the consensus revenue estimate of $109.73 million.

What price target have analysts set for NVRO?

12 brokers have issued 1-year target prices for Nevro's shares. Their forecasts range from $65.00 to $150.00. On average, they expect Nevro's share price to reach $103.83 in the next twelve months. This suggests that the stock has a possible downside of 28.0%. View Analyst Price Targets for Nevro.

What is the consensus analysts' recommendation for Nevro?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 1 sell rating, 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nevro.

Has Nevro been receiving favorable news coverage?

Media coverage about NVRO stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Nevro earned a media sentiment score of 0.7 on InfoTrie's scale. They also gave news stories about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Nevro.

Are investors shorting Nevro?

Nevro saw a decline in short interest during the month of January. As of January 31st, there was short interest totalling 2,610,000 shares, a decline of 9.1% from the January 15th total of 2,870,000 shares. Based on an average daily volume of 443,000 shares, the days-to-cover ratio is presently 5.9 days. Currently, 8.8% of the company's stock are sold short. View Nevro's Current Options Chain.

Who are some of Nevro's key competitors?

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), Gilead Sciences (GILD), AbbVie (ABBV), Incyte (INCY), Micron Technology (MU), Starbucks (SBUX), ABIOMED (ABMD), Celgene (CELG) and Intercept Pharmaceuticals (ICPT).

Who are Nevro's key executives?

Nevro's management team includes the folowing people:
  • Mr. Andrew H. Galligan, Chief Financial Officer (Age 63)
  • Mr. Patrick Schmitz, VP of Operations (Age 59)
  • Mr. Kashif Rashid, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 45)
  • Mr. Doug Alleavitch, VP of Quality (Age 58)
  • Mr. D. Keith Grossman, Pres, CEO & Director (Age 59)

Who are Nevro's major shareholders?

Nevro's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Fred Alger Management LLC (6.17%), Franklin Resources Inc. (4.30%), Jackson Square Partners LLC (3.91%), Perceptive Advisors LLC (2.46%), State Street Corp (2.29%) and Lord Abbett & CO. LLC (1.92%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Elizabeth H Weatherman, Kevin C Oboyle, Shawn Mccormick and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro.

Which major investors are selling Nevro stock?

NVRO stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Jackson Square Partners LLC, Perceptive Advisors LLC, Point72 Asset Management L.P., Franklin Resources Inc., Barclays PLC, Spark Investment Management LLC and Lord Abbett & CO. LLC. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan, Doug Alleavitch and Shawn Mccormick. View Insider Buying and Selling for Nevro.

Which major investors are buying Nevro stock?

NVRO stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., Renaissance Technologies LLC, Partner Fund Management L.P., AXA, Man Group plc, State of New Jersey Common Pension Fund D and Delta Investment Management LLC. Company insiders that have bought Nevro stock in the last two years include Elizabeth H Weatherman and Kevin C Oboyle. View Insider Buying and Selling for Nevro.

How do I buy shares of Nevro?

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Nevro's stock price today?

One share of NVRO stock can currently be purchased for approximately $144.31.

How big of a company is Nevro?

Nevro has a market capitalization of $4.47 billion and generates $387.29 million in revenue each year. The medical equipment provider earns $-49,210,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Nevro employs 804 workers across the globe.View Additional Information About Nevro.

What is Nevro's official website?

The official website for Nevro is http://www.nevro.com/.

How can I contact Nevro?

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]


MarketBeat Community Rating for Nevro (NYSE NVRO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  422 (Thanks for Voting!)
Underperform Votes:  298 (Thanks for Voting!)
Total Votes:  720
MarketBeat's community ratings are surveys of what our community members think about Nevro and other stocks. Vote "Outperform" if you believe NVRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Featured Article: Inverted Yield Curve

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel